Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)
Summary:
The NCI seeks parties interested in licensing this library of cell lines stably expressing tumor-specific antigens and HLAs.
Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants
Description of Technology:
Extracellular Vesicles (EVs), including exosomes and microvesicles, are nanometer-sized membranous vesicles that can carry different types of cargos, such as proteins, nucleic acids and metabolites. EVs are produced and released by most cell types. They act as biological mediators for intercellular communication via delivery of their cargos. This unique ability spurred translational research interest for targeted delivery of therapeutic molecules to treat a wide range of diseases.
Molecular Nanotags for Detection of Single Molecules
Description of Technology:
Biological nanoparticles, like extracellular vesicles (EVs), possess unique biological characteristics making them attractive therapeutic agents, targets, or disease biomarkers. However, their use is hindered by the lack of tools available to accurately detect, sort, and analyze. Flow cytometers are used to sort and study individual cells. But, they are unable to detect and sort nanomaterials smaller than 200 nanometers with single epitope sensitivity.
Mice, Organs, and Mouse Alleles Carrying Germline and Conditional Deletions of the Zbtb7b Gene
Summary:
The NCI seeks parties interested in licensing this mouse model, including the mice, organs, tissues, and other derivatives from mice carrying deletions of the Zbtb7b gene.
T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools
Summary:
The Surgery Branch seeks licensees for research use of TCRs targeting EGFR L858R mutation.
CODEFACS and LIRICS: Computation Tools for Identifying Cell-Type Specific Gene Expression Levels in Tumors and Other Types of Samples
Description of Technology:
The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities.
SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation
Description of Technology:
The Transforming Growth Factor Beta (TGF-ß) ligands (i.e., TGF-ß1, -ß2, -ß3) are key regulatory proteins in animal physiology. Disruption of normal TGF-ß signaling is associated with many diseases from cancer to fibrosis. In mice and humans, TGF-ß activates TGF-ß receptors (e.g., TGFBR1), which activates SMAD proteins that alter gene expression and contribute to tumorigenesis. Reliable animal models are essential for the study of TGF-ß signaling.
Adriamycin-Resistant Ovarian Tumor Cell Line, NCI/ADR-RES
Summary:
NCI is seeking parties to non-exclusively license the ADR-RES cell line.
Description of Technology:
Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity of cancer treatment.
Human Synovial Sarcoma Cell Line A2243
Summary:
NCI is seeking parties to non-exclusively license the A2243 human synovial sarcoma cell line.
CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles
Description of Technology:
Cytokines are a broad category of intercellular signaling proteins that are critical for intercellular communication in human health and disease. However, systematic profiling of cytokine signaling activities has remained challenging due to the short half-lives of cytokines, and the pleiotropic functions and redundancy of cytokine activities within specific cellular contexts.